Association between splenic volume changes and prognosis in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy.

ABSTRACT:

Background and aim

The prognostic value of splenic volume (SV) in patients with advanced gastric cancer receiving chemotherapy combined with immunotherapy remains unclear. This study aimed to evaluate the association between CT-assessed changes in SV and clinical outcomes, exploring its potential as a prognostic biomarker.

Methods

This retrospective cohort study included 138 advanced gastric cancer patients receiving chemotherapy combined with immunotherapy. Patients were stratified into an increased group (ΔSV > 14%, n = 87) and a non-increased group (ΔSV ≤ 14%, n = 51) based on the optimal cutoff value of 14% for the annualized change in splenic volume (ΔSV). Kaplan-Meier survival analysis, Cox proportional hazards models, and restricted cubic spline analyses were used to

SUBMITTER: Li Z 

PROVIDER: S-EPMC12932240 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature